Skip to content

Study · Randomized controlled trial · n = 135 · 1999

8 results

A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma.

Ingle JN, Suman VJ, Kardinal CG, Krook JE, Mailliard JA, Veeder MH, Loprinzi CL, Dalton RJ, Hartmann LC, Conover CA, Pollak MN

Cancer1 Mar 1999Cited by 46 (Europe PMC)

PMID10189133 (opens in a new tab)DOI10.1002/(sici)1097-0142(19990315)85:6<1284::aid-cncr10>3.0.co;2-p (opens in a new tab)PepBankPUB-10189133
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In metastatic breast carcinoma, tamoxifen plus octreotide had median progression time of 10.3 months versus 14.2 months with tamoxifen alone.

    In plain wordsIn metastatic breast cancer, progression time was 10.3 months with tamoxifen plus octreotide versus 14.2 months with tamoxifen alone.

    Peptide
    Octreotide
    Outcome
    DecreaseMedian time to progression
    Study

    n = 135

    Comparator
    Tamoxifen alone
    Outcome group
    Tumor Progression · Cancer
    Studied dose
    150 microg thrice daily · subcutaneousAs given in this study (human).

    Measurements

    Median time to progression
    14.2 months
    tamoxifen alone
    Median time to progression
    10.3 months
    tamoxifen plus octreotide

    Source sentences

    Summary
    The median time to progression was estimated to be 14.2 months with TAM and 10.3 months with TAM plus octreotide.
    1 context sentence
    Summary · context
    One hundred thirty-five eligible postmenopausal women with metastatic breast carcinoma were randomized to TAM (10 mg twice daily) alone or combined with octreotide 150 microg (administered subcutaneously thrice daily).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In metastatic breast carcinoma, progression-free survival did not differ significantly between tamoxifen plus octreotide and tamoxifen alone (P = 0.26).

    In plain wordsIn metastatic breast cancer, progression-free survival did not differ significantly between tamoxifen plus octreotide and tamoxifen alone.

    Peptide
    Octreotide
    Outcome
    No significant changeProgression-free survival
    Study

    n = 135

    Comparator
    Tamoxifen alone
    Outcome group
    Tumor Progression · Cancer
    Studied dose
    150 microg thrice daily · subcutaneousAs given in this study (human).

    Measurements

    Progression hazard ratio
    0.81 ratio
    TAM/TAM + octreotide
    95% confidence interval
    0.56 to 1.17 ratio
    TAM/TAM + octreotide
    P value for progression free survival distribution
    0.26 P
    tamoxifen plus octreotide versus tamoxifen alone

    Source sentences

    Summary
    The distribution of progression free survival times revealed no significant difference (P = 0.26), and the progression hazard ratio (TAM/TAM + octreotide) was 0.81 (95% confidence interval [CI], 0.56-1.17).
    1 context sentence
    Summary · context
    One hundred thirty-five eligible postmenopausal women with metastatic breast carcinoma were randomized to TAM (10 mg twice daily) alone or combined with octreotide 150 microg (administered subcutaneously thrice daily).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In metastatic breast carcinoma, survival did not differ significantly between tamoxifen plus octreotide and tamoxifen alone (P = 0.92).

    In plain wordsIn metastatic breast cancer, survival did not differ significantly between tamoxifen plus octreotide and tamoxifen alone.

    Peptide
    Octreotide
    Outcome
    No significant changeOverall survival
    Study

    n = 135

    Comparator
    Tamoxifen alone
    Outcome group
    Mortality · Cancer
    Studied dose
    150 microg thrice daily · subcutaneousAs given in this study (human).

    Measurements

    Death hazard ratio
    0.98 ratio
    TAM/TAM + octreotide
    95% confidence interval
    0.62 to 1.55 ratio
    TAM/TAM + octreotide
    P value for survival distribution
    0.92 P
    tamoxifen plus octreotide versus tamoxifen alone

    Source sentences

    Summary
    The distribution of survival times revealed no significant difference (P = 0.92), and the death hazard ratio was 0.98 (95% CI, 0.62-1.55).
    1 context sentence
    Summary · context
    One hundred thirty-five eligible postmenopausal women with metastatic breast carcinoma were randomized to TAM (10 mg twice daily) alone or combined with octreotide 150 microg (administered subcutaneously thrice daily).
  4. 04HumanRandomized controlled trialSafety outcome

    In metastatic breast carcinoma, nausea was more frequent with tamoxifen plus octreotide than with tamoxifen alone.

    In plain wordsIn metastatic breast cancer, nausea was more frequent with tamoxifen plus octreotide than with tamoxifen alone.

    Peptide
    Octreotide
    Outcome
    IncreaseNausea
    Study

    n = 135

    Comparator
    Tamoxifen alone
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    150 microg thrice daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Patients who received TAM plus octreotide had higher incidences of nausea, diarrhea, and steatorrhea.
    1 context sentence
    Summary · context
    One hundred thirty-five eligible postmenopausal women with metastatic breast carcinoma were randomized to TAM (10 mg twice daily) alone or combined with octreotide 150 microg (administered subcutaneously thrice daily).
  5. 05HumanRandomized controlled trialSafety outcome

    In metastatic breast carcinoma, diarrhea was more frequent with tamoxifen plus octreotide than with tamoxifen alone.

    In plain wordsIn metastatic breast cancer, diarrhea was more frequent with tamoxifen plus octreotide than with tamoxifen alone.

    Peptide
    Octreotide
    Outcome
    IncreaseDiarrhea
    Study

    n = 135

    Comparator
    Tamoxifen alone
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    150 microg thrice daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Patients who received TAM plus octreotide had higher incidences of nausea, diarrhea, and steatorrhea.
    1 context sentence
    Summary · context
    One hundred thirty-five eligible postmenopausal women with metastatic breast carcinoma were randomized to TAM (10 mg twice daily) alone or combined with octreotide 150 microg (administered subcutaneously thrice daily).
  6. 06HumanRandomized controlled trialSafety outcome

    In metastatic breast carcinoma, steatorrhea was more frequent with tamoxifen plus octreotide than with tamoxifen alone.

    In plain wordsIn metastatic breast cancer, fatty stools were more frequent with tamoxifen plus octreotide than with tamoxifen alone.

    Peptide
    Octreotide
    Outcome
    IncreaseSteatorrhea
    Study

    n = 135

    Comparator
    Tamoxifen alone
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    150 microg thrice daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Patients who received TAM plus octreotide had higher incidences of nausea, diarrhea, and steatorrhea.
    1 context sentence
    Summary · context
    One hundred thirty-five eligible postmenopausal women with metastatic breast carcinoma were randomized to TAM (10 mg twice daily) alone or combined with octreotide 150 microg (administered subcutaneously thrice daily).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In evaluable metastatic breast carcinoma, objective response was 43% with tamoxifen plus octreotide versus 49% with tamoxifen alone (P = 0.70).

    In plain wordsIn metastatic breast cancer, response was 43% with tamoxifen plus octreotide versus 49% with tamoxifen alone, without a significant difference.

    Peptide
    Octreotide
    Outcome
    DecreaseObjective response rate
    Study

    n = 106

    Comparator
    Tamoxifen alone
    Outcome group
    Cancer treatment response · Cancer
    Studied dose
    150 microg thrice daily · subcutaneousAs given in this study (human).

    Measurements

    Objective response rate
    49%
    tamoxifen alone
    Objective response rate
    43%
    tamoxifen plus octreotide
    P value
    0.7 P
    tamoxifen plus octreotide versus tamoxifen alone

    Source sentences

    Summary
    When the 106 patients with measurable or evaluable disease were considered, the objective response rate was 49% with TAM alone and 43% with TAM plus octreotide (P = 0.70).
    1 context sentence
    Summary · context
    One hundred thirty-five eligible postmenopausal women with metastatic breast carcinoma were randomized to TAM (10 mg twice daily) alone or combined with octreotide 150 microg (administered subcutaneously thrice daily).
  8. 08HumanRandomized controlled trialActivity measurement

    In metastatic breast carcinoma, serum IGF-I declined more after 3-6 weeks with tamoxifen plus octreotide than with tamoxifen alone (P < 0.01).

    In plain wordsIn metastatic breast cancer, IGF-I declined more with tamoxifen plus octreotide than with tamoxifen alone.

    Peptide
    Octreotide
    Outcome
    DecreaseSerum IGF-I decline
    Study

    n = 18

    Comparator
    Tamoxifen alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    150 microg thrice daily · subcutaneous · 3-6 weeksAs given in this study (human).

    Measurements

    P value for percentage decline in serum IGF-I
    < 0.01 P
    tamoxifen plus octreotide versus tamoxifen alone

    Source sentences

    Summary
    The percentage of decline in serum IGF-I, from pretreatment levels to those following 3-6 weeks of treatment, was significantly greater (P < 0.01) with TAM plus octreotide than with TAM alone.
    2 context sentences
    Summary · context
    A cohort of 18 patients was evaluated for the impact of treatment on serum IGF-I, free IGF-I, IGF binding protein 3 levels, and total IGF binding capacity.
    Summary · context
    One hundred thirty-five eligible postmenopausal women with metastatic breast carcinoma were randomized to TAM (10 mg twice daily) alone or combined with octreotide 150 microg (administered subcutaneously thrice daily).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.